Cadrenal Therapeutics (CVKD) Change in Account Payables (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Change in Account Payables of $174146.0 for Q1 2026, up 376.64% sequentially from $36536.0 in Q4 2025, and up 177.72% YoY from $62705.4 in Q1 2025.
Cadrenal Therapeutics (CVKD) Change in Account Payables (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Change in Account Payables for 5 years, with the latest figure at $174146.0 in Q1 2026.
- Quarterly Change in Account Payables rose 177.72% year-over-year to $174146.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$453593.0 (down 151.66% YoY) and the FY2025 annual result came in at -$851805.0, down 163.8% from the prior year.
- Change in Account Payables grew to $174146.0 in Q1 2026 per CVKD's latest filing, from $36536.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.0 million in Q4 2024 and troughed at -$382793.0 in Q2 2025.
- A 5-year average of $48518.2 and a median of $36536.0 in 2025 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables plunged 1986.73% in 2023, then jumped 3818.96% in 2024.
- Over 5 years, Change in Account Payables stood at $96676.0 in 2022, then sank by 73.46% to $25661.0 in 2023, then surged by 3818.96% to $1.0 million in 2024, then sank by 96.37% to $36536.0 in 2025, then jumped by 376.64% to $174146.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $174146.0, $36536.0, and -$281482.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | 47,104.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47,104.00 |
| Jun 30, 2026 | 47,104.00 |
| Mar 31, 2026 | 174,146.00 |
| Mar 31, 2026 | 174,146.00 |
| Dec 31, 2025 | 36,536.00 |
| Dec 31, 2025 | 36,536.00 |
| Sep 30, 2025 | -281,482.00 |
| Sep 30, 2025 | -281,482.00 |
| Jun 30, 2025 | -382,793.00 |
| Jun 30, 2025 | -382,793.00 |
| Mar 31, 2025 | -224,066.00 |
| Mar 31, 2025 | -224,066.00 |
| Dec 31, 2024 | 1.01 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | -262,695.00 |
| Sep 30, 2024 | -262,695.00 |
| Jun 30, 2024 | 359,145.00 |
| Jun 30, 2024 | 359,145.00 |
| Mar 31, 2024 | 233,054.00 |
| Mar 31, 2024 | 233,054.00 |